Abstract
Abstract not available.
Highlights
In a new microencapsulated formulation (E-BPO Cream, 5%), the drug is entrapped in silica microcapsules
The efficacy, safety, and tolerability of E-BPO Cream, 5% were evaluated in two identical randomized, double-blind phase 3 trials which demonstrated significant superiority of E-BPO versus vehicle for percentage of patients achieving success on the Investigators Global Assessment (IGA) and reducing the number of lesions.[2]
E-BPO Cream, 5% was well tolerated with adverse events (AEs) and cutaneous safety and tolerability comparable to that for vehicle.[2]
Summary
In a new microencapsulated formulation (E-BPO Cream, 5%), the drug is entrapped in silica microcapsules. This extends drug delivery time to improve efficacy and reduce the potential for skin irritation.[1]. The efficacy, safety, and tolerability of E-BPO Cream, 5% were evaluated in two identical randomized, double-blind phase 3 trials which demonstrated significant superiority of E-BPO versus vehicle for percentage of patients achieving success (clear or almost clear) on the Investigators Global Assessment (IGA) and reducing the number of lesions.2 E-BPO Cream, 5% was well tolerated with adverse events (AEs) and cutaneous safety and tolerability comparable to that for vehicle.[2]. This report summarizes results from an analysis of younger (
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
